FIELD: medicine; pharmaceutical engineering.
SUBSTANCE: pharmaceutical composition COMPRISES 5-(2-pyrazinyl)-4-methyl-1,2-dithyol -3-thion (oltipraze) and dimethyl-4,4'-dimetoxi-5,6,5',6'-dimethylene-dioxybiphenyl-2,2' dicarboxilate (DDB) as the main components. Oltipraze: DDB proportion is preferentially equal to 50-1:1-50, the most preferential being 5:1.
EFFECT: enhanced effectiveness of treatment.
6 cl, 6 dwg, 9 tbl
| Title |
Year |
Author |
Number |
| APPLYING OLTIPRAZ FOR PROPHYLAXIS AND TREATMENT OF LIVER FIBROSIS AND CIRRHOSIS AND OLTIPRAZ-CONTAINING PHARMACEUTICAL COMPOSITION |
2001 |
- Kim Sang Geon
- Kang Keon Vuk
|
RU2258509C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOL-THIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASES MEDIATED BY HIGH LXR-ALPHA EXPRESSION |
2009 |
- Kim San Gon
- Ki Sun Khvan
- Khvan Son Khvan
|
RU2491065C2 |
| COMPOSITION FOR TREATING AND PREVENTING BENIGN PROSTATIC HYPERPLASIA |
2017 |
|
RU2683649C1 |
| COMPOSITION FOR TREATING AND PREVENTING BENIGN PROSTATIC HYPERPLASIA |
2014 |
|
RU2661596C2 |
| NEW PEPTIDE AND ITS USE |
2010 |
- Kim, Hae Jin
- Moon, Eun Joung
- Kim, Yang Seon
- Kwon, Young Joon
|
RU2498992C1 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES |
2015 |
- Kim Soon Kha
- Kim Khioung Dzin
- Park Kheui Sul
- Akhn Seo Khiun
- Shong Min Kho
- Chung Khio Kiun
|
RU2664696C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES |
2021 |
- Kim, Yunki
- Kim, Minsun
- Kim, Ryuryun
- Choi, Jaeyoung
- Yim, Yeseal
- Shim, Myungbo
- Han, Daye
- Im, Daeseong
- Park, Sungjin
|
RU2822001C1 |
| THERAPEUTIC AGENT FOR LIVER DISEASES |
2018 |
- Moon, Sung Hwan
- Lee, Soo Jin
- Lee, Sung Chan
- Bae, Yun Soo
|
RU2723686C1 |
| CENICRIVIROC FOR TREATING FIBROSIS |
2015 |
|
RU2724339C2 |
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE |
2021 |
- Moon, Sung Hwan
- Lee, Soo Jin
- Yu, Hyunkyung
- Goh, Yoo-Kyung
|
RU2817989C1 |
